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Introduction
Over the past few years, there has been significant
progress in the surgical management of various liver
diseases as a result of advances in surgical technolo-
gies and the effort of liver surgeons around the world
to improve the treatment outcome of their patients
through active research. However, partly because of
the paucity of high-level evidence in the literature,
there are still a lot of controversies in several areas in
liver surgery. The programme of the 7th World
Congress of the International Hepato-pancreato-bili-
ary Association held in Edinburgh on 37 September
2006 has incorporated most of the recent advances
and controversies in liver surgery. The main topics
presented and discussed in various keynote lectures,
symposia, and free paper sessions of the Congress can
be summarized into five areas: advances in surgical
techniques of liver resection, role of ablative therapies,
applications of liver transplantation, recent trends
in management of colorectal liver metastasis, and
controversies in management of hepatocellular carci-
noma (HCC).
Advances in techniques of liver resection
The main challenge of liver resection is the control of
bleeding during liver transection. Finger fracture or
clamp crushing are the conventional techniques of
liver transection widely used in many centers. Ultra-
sonic dissection, introduced in the early 1990s, has
become a standard technique in other centers. In
recent years, a few other techniques or instruments
based on new technologies have been developed, with
an aim towards bloodless hepatic resection. These
include the water jet, harmonic scalpel, Ligasure,
Tissuelink and radiofrequency-assisted liver transec-
tion. The pros and cons of these techniques were
presented in a keynote lecture by the author, with a
particular emphasis on the evidence from a few
randomized trials comparing different techniques
recently available in the literature [14]. In addition
to advances in technologies and instruments, the
understanding of the importance of inflow vascular
control and low central venous pressures is another
major contribution to lower blood loss in hepatic
resection. The role of the Pringle maneuver was the
subject of debate in a session in the Congress. While a
previous randomized trial from the author’s institu-
tion showed that intermittent Pringle maneuver
reduced blood loss during liver resection [5], a more
recent randomized trial conducted by an Italian group
showed no benefit of the use of the Pringle maneuver
[6]. The recent demonstration of an adverse effect of
ischemic-reperfusion injury on long-term tumor re-
currence in the liver remnant in an animal model by a
Dutch group raised a concern about the use of the
Pringle maneuver [7]. In the Congress, the same
group presented a paper showing that prolonged use
of the Pringle maneuver in liver resection for color-
ectal metastasis significantly reduced the disease-free
survival of patients based on a retrospective analysis
[8]. This further intensified the debate on the use of
the Pringle maneuver. Data from a prospectively
randomized cohort are required to provide more
definite evidence regarding the effect of the Pringle
maneuver on long-term tumor recurrence after resec-
tion of liver cancers. However, in experienced centers,
low blood loss and transfusion rates can now be
achieved in liver resection without the Pringle man-
euver [9].
The other important recent advance in liver surgery
is laparoscopic liver resection, which started later than
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laparoscopic surgery in other intra-abdominal proce-
dures because of difficulty in control of bleeding
during liver transection in the laparoscopic setting.
The new instruments developed for liver transection
can all be used in the laparoscopic setting, allowing
better control of liver transection. As a result, there
has been rapid development of laparoscopic resection
in recent years, with about 1000 cases reported in the
literature to date. While earlier reports contended that
laparoscopic liver resection should be confined to
resection of anterior segments and left lateral seg-
ments of the liver, in this Congress, a few groups from
experienced centers have demonstrated that laparo-
scopic right or left hepatectomy is feasible and safe in
their hands. In a recent report, Cherqui et al. [10]
demonstrated that laparoscopic liver resection can
achieve mid-term survival results similar to open
resection for patients with HCC.
Increasing role of liver ablation
Ablative therapies, especially radiofrequency ablation
(RFA), are gaining popularity in the management of
liver malignancies. In a symposium in the Congress,
the importance of performing RFA in experienced
centers to reduce morbidity and increase complete
ablation rate was emphasized based on experience
reported in two recent publications [11,12]. Further-
more, the role of surgeons in ablation of RFA was
highlighted by a recent study that suggested that a
surgical approach achieved a more complete tumor
eradication and lower tumor recurrence rate com-
pared with a percutaneous approach in a meta-
analysis of 5224 cases of RFA for liver malignancies
reported in the literature [13]. The role of surgical
ablation is further supported by a study from the
author’s group that showed that RFA by surgical
approaches resulted in significantly better survival
compared with the percutaneous approach for pa-
tients with HCC 35 cm in diameter [14]. Microwave
ablation is another modality of thermal ablation that
could achieve rapid ablation of a large volume of liver
with recent development of a more powerful micro-
wave system [15]. Encouraging clinical data presented
in the Congress suggested that ablation of large
tumors using the new generation of microwave system
is safe and effective.
Whether thermal ablation such as RFA can
replace resection as a curative treatment for small
HCCB/5 cm in diameter is a controversial subject
that has been discussed in the Congress. With its
minimal invasiveness and safety, RFA is an attractive
option for patients, but whether it could achieve
similar long-term oncological results to liver resection
remains unclear. Two non-randomized studies sug-
gested that resection is associated with a lower tumor
recurrence rate compared with RFA [16,17], and one
of the studies also demonstrated better long-term
survival with resection [16]. However, a recent
randomized controlled study suggested that RFA
may achieve similar long-term recurrence-free and
overall survival compared with resection [18]. Further
randomized trials are needed to more clearly define
the role of RFA versus resection for small HCC.
Expanding the application of liver
transplantation
Liver transplantation is the best treatment option for
end-stage liver disease, including early HCC asso-
ciated with advanced cirrhosis. However, the applica-
tion of liver transplantation is severely limited by the
shortage of deceased donor grafts, hence many
patients die from progression of the disease while
waiting for a graft. In the Congress, several measures
to expand the use of liver transplantation have been
presented and discussed, including the use of mar-
ginal grafts (age/65 years, macrosteatosis/40%,
cold ischemic time/12 h, hepatitis B or C infection,
etc.), non-heart-beating donor grafts, split liver grafts,
and live donor grafts.
The use of marginal grafts is associated with in-
creased risk of primary graft dysfunction but no
significant effect on mortality or long-term survival
provided that re-transplantation is a possible option
[19]. Good outcome can be achieved with the use of
split grafts; however, its application is limited by logistic
restrictions in many centers [20]. The use of non-heart-
beating donor grafts requires careful graft selection to
ensure reasonable graft quality so as to reduce the risk
of early graft failure or ischemic cholangiopathy asso-
ciated with prolonged warm ischemia [21]. Liver donor
transplantation provides good quality grafts and a
much larger potential pool of donors compared with
other types of grafts. However, the risk to the donor and
the problem of small-for-size grafts limits its applica-
tion. Nevertheless, there has been increasing use of live
donor liver transplantation worldwide. A study of 1709
patients with liver donor liver transplantation per-
formed in 64 European centers presented in the
Congress reported favorable results with a donor
mortality rate of 0.23%, 5-year graft survival of 70%,
and 5-year recipient survival of 76% [22].
The availability of graft also affects the role of re-
transplantation, which was another topic discussed
in the Congress. Technical advances have reduced
the need for re-transplantation for vascular or biliary
complications, and improved immunosuppression has
decreased re-transplantation for graft rejection. On
the other hand, increased use of marginal grafts has
led to increased requirement for re-transplantation,
and the problem of recurrent viral disease, in parti-
cular hepatitis C viral infection, remains a common
indication for re-transplantation in the long term [23].
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Recent trends in management of colorectal liver
metastasis
The management of colorectal liver metastasis was
the theme of one of the symposia in the Congress.
Recent availability of more effective chemotherapy
regimens for colorectal cancer has resulted in more
patients with initially unresectable colorectal liver
metastasis being downsized to become resectable.
With chemotherapy regimens based on oxaliplatin or
irinotecan, it was estimated that 1530% of patients
with initially unresectable colorectal liver metastases
have adequate reduction in tumor size or number to
become resectable, and a 5-year survival rate of 30%
after resection of such cases has been reported [24].
The role of neoadjuvant chemotherapy in patients
with resectable colorectal liver metastasis is uncertain,
with no data from prospective randomized clinical
trials available in the literature.
While newer chemotherapeutic agents have led to
increased tumor response and resectability of color-
ectal liver metastasis, the risk of liver resection
associated with use of such agents is a concern
discussed in the Congress. Recent studies have shown
increased risk of liver resection in patients with
preoperative chemotherapy due to the effects of
vasculopathy, hepatocyte necrosis, and increased
bleeding [24,25]. In one recent study, preoperative
chemotherapy with an irinotecan-based regimen was
associated with a five times higher risk of steatohepa-
titis compared with no chemotherapy (20.2% vs
4.4%), which in turn was associated with increased
90-day mortality (14.7% vs 1.6%) [26]. The impact
of preoperative chemotherapy on morbidity and
mortality of liver resection and strategies to reduce
such adverse effects of chemotherapy for colorectal
liver metastasis deserve further studies, as liver
surgeons are faced with more and more patients
treated with chemotherapy.
Another issue discussed in the Congress was the
role of simultaneous resection of colorectal primary
cancer and liver resection for synchronous liver
metastasis. Recent studies have shown that simulta-
neous colorectal and liver resection is safe for most
patients [27,28]. However, the selection criteria for
simultaneous or staged resection remain uncertain.
Patients with more aggressive tumor biology may
benefit from chemotherapy after resection of color-
ectal primary tumors before proceeding to liver
resection for metastasis, but this requires further
studies.
Controversies in management of hepatocellular
carcinoma
A few areas of controversies in the surgical manage-
ment of HCC were addressed in the Congress. In
addition to the issue of whether RFA can replace
resection for small HCC, the issue of resection or
transplantation for early HCC in Child-Pugh class A
cirrhotic patients is also a controversial issue. While
some authors suggested primary liver transplantation
as the first-line treatment for early HCC even for
patients with preserved liver function [29], others
advocated resection as the first-line treatment, with
transplantation as a possible salvage treatment for
recurrent HCC [30,31]. A study presented as a free
paper in the Congress supported the latter strategy by
showing that the overall survival after resection was
comparable to that after liver transplantation in
patients with HCC fulfilling the Milan criteria [32].
Whether bridge therapy is required and the opti-
mum bridge therapy before transplantation of HCC
was another subject of debate in the Congress. TACE
and RFA are the frequently used bridge therapies
prior to liver transplantation for HCC, but there are
insufficient data to indicate that these bridge therapies
improve patients’ outcomes [33,34]. Others have
advocated resection as a bridge therapy, with the
advantage of histologic examination of the tumor, but
the survival benefit of such an approach remains to be
demonstrated [30]. Bridge therapy may not be
necessary when the waiting time for liver transplanta-
tion is shorter than 6 months.
Conclusions
There has been significant progress in liver surgery in
recent years. Technical advances in liver resection and
ablation therapies, together with increasing applica-
tion of liver transplantation, have benefited more
patients with benign or malignant liver diseases.
However, there are a number of controversial issues
that need to be resolved. The paucity of randomized
controlled trials in the literature has hindered progress
in these areas. Such trials are important in guiding
evidence-based surgical management of liver diseases
and should be the major focus of future research in
liver surgery.
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